Ginkgo biloba
This article was originally published in The Tan Sheet
Executive Summary
Researchers in the NIH-funded study on the botanical and prevention of dementia in the elderly have begun enrolling 3,000 participants, rather than 2,000 as initially planned. The cohort size has been adjusted to boost the statistical results of the study. Last fall, NCCAM and the National Institute on Aging awarded $15 mil. for the six-year study to the University of Pittsburgh School of Medicine (1"The Tan Sheet" Oct. 4, 1999, p. 4). The Dr. Willmar Schwabe company of Germany will supply the ginkgo extract - EGb 761 - for the trial. A pharmaceutical grade preparation, the extract is marketed as a prescription drug in Germany. The company will donate 12 mil. tablets for the study at an estimated market value of roughly $4 mil. Schwabe owns 50% of Murdock Madaus Schwabe, of which Nature's Way is the main marketing and distribution arm. Nature's Way markets EGb 761-containing Ginkgold